E-mail this pagePrint
Global Smoking Cessation Market Analysis & Forecasts Preparing for the first blockbuster Publication Date   December 2007 Publisher   VISIONGAIN Product Type   Report Pages   151 ISBN Number   not applicable Product Code   VISG01

Cigarette smoking is the most important source of preventable and premature morbidity worldwide. Currently, the number of smokers across the globe is estimated at 1.3 billion. Political moves are leading to national bans of smoking in public places, with the long-term aim to reduce the cost to the health sector. But what will be the short-term spending on smoking cessation therapies?
 
In 2007 visiongain believes the anti-smoking market to be worth $1.7 billion. This is a growth of 37% from the year before. This latest report from visiongain, Global Smoking Cessation Market Analysis & Forecasts - preparing for the first blockbuster, explains just how this market will experience growth over the medium term future. Also do you know what the drivers and restraints of the market are? This report not only reveals these, but also details what strategies can be used to maximize profits from the drivers and restraints.

The report examines key smoking cessation markets such as:
- US
- Japan
- Canada
- Germany
- France
- Italy
- Spain
- UK
- Sweden
- Australia

In this report each one of these disease areas is examined in terms of market growth and revenue. We examine how current and new drug treatments will take hold in each market and which companies will succeed in that markets.
 
According to the findings of this new report, Visiongain reveals that the nicotine vaccine market will generate over $1 billion plus that Pfizer's nicotinic receptor will be the markets first blockbuster drug.

Can any of these drugs compete with the OTC market leaders? How will GSK's Zyban be effected with direct competition from Chantix/ Champix? However are there any others which can compete with this for market share or beat its dominance? This report answers that question, with an analysis of other players in the market.
 
The report provides in-depth market analysis upon these areas, and extensively identifies both prescription and OTC smoking cessation drugs by product type. The study also assess' the challenges faced by anti-smoking companies, and what exciting market opportunities exist in this up- and-coming therapeutic area.
 
Why You Must Buy This Report?
This report features tables, graphs and charts, news, insights, the latest developments and an in depth survey of the anti-smoking market with up-to-date analysis. This report is a vital addition to gaining an understanding of this profitable market sector and will give your company 'the edge' on your competitors.

Unique benefits to you when you order this report:
- Immediate access through our exclusive Reading Room
- You can access your report whichever country you are in without using harddrive space
- Primary research throughout. You will not find this information anywhere else
- Report stored in your reading room for ever
- Full searchable report when you buy the company or corporate editions
- Copies can be printed off for offline reading
- Packed with charts, analysis, figures, graphs and tables

Table of Contents

1. Executive Summary

2. Introduction
2.1 Smoking – Currently 1.3 Billion Smokers Worldwide
2.2 Second-hand smoke/Passive smoking Causes Lung Cancer
2.3 Medical Research in Smoking Related Problems
      2.3.1 Effects of Smoking in Lung Cancer the Most Lethal of all Cancers Worldwide
      2.3.2 Effects of Smoking in Emphysema
      2.3.3 Effects of Smoking in Heart Disease
2.4 Cigarette Smoking Signs and Symptoms
2.5 Scope of the Report
2.6 Aims and Objectives

3. Social, Political and Economic effects
3.1 Current Policy & Expansion of Smoking Bans
      3.1.1 Effects of Smoking Bans on Health
      3.1.2 Financial Effects of Smoking Bans on Businesses
      3.1.3 Outdoor Smoking Bans
      3.1.4 Concerns over Smoking Bans
3.2 Can Complete Smoking Cessation Increase Healthcare Costs?
3.3 Anti-Smoking Organizations and Their Lobby
3.3.1 Establishing a Campaign to Assist Fighting Tobacco Addiction
3.4 Tobacco Prices: A Key Strategy in Reducing Smokers
3.5 Using Anti-Smoking Operations as a Health Promotion Campaign
3.6 Economic Impact on the Tobacco Industry
3.7 New Anti-Counterfeit Technology to Reduce Cigarette Smuggling

4. Can Drugs Deal With Addiction & Nicotine?
4.1 Overcoming the Psychological Dependence that is Addiction
      4.1.1 Fighting the Psychological Addiction
      4.1.2 What Areas to Target in the Fight against Physiological Addiction
      4.1.3 Regulatory Control of Addiction
4.2 What the Pharma Industry is up against if Nicotine is the Hardest Addiction to Break
     4.2.1 The Effects of Nicotine
     4.2.2 Effects of Nicotine in the Brain
     4.2.3 Combating the Effects of Nicotine in the Body
     4.2.4 The Symptoms of Nicotine Toxicity
     4.2.5 How to Assess the Level of Nicotine Addiction?

5. Treatment Overview
5.1 Smoking Cessation Aids
5.2 Nicotine Replacement Therapy (NRT)
      5.2.1 Can Any Product Compete with a OTC Nicotine Gum
               5.2.1.1 Nicorette - The Leading NRT Smoking Cessation Product
     5.2.2 A More Rapid Effect through Nicotine Inhalers
     5.2.3 Specific Quantities Through Nicotine Patches
     5.2.4 Options Available in Nicotine Lozenge
     5.2.5 Overcoming Sudden Craving Through Nicotine Nasal Spray
     5.2.6 NRT Drug Summary and Sales
5.3 The Antidepressant Approach: Bupropion (Zyban)
      5.3.1 However Zyban’s Revenue is Decreasing
5.4 Market Capturing by Varenicline (Chantix/ Champix)
     5.4.1 Chantix/Champix Set to Become a Future Blockbuster?
5.5 Other Smoking Cessation Methods
    5.5.1 Behaviour Modification Therapy
    5.5.2 Cold Turkey
    5.5.3 Hypnosis
    5.5.4 Acupuncture

6. Pipeline
6.1 Anti-Smoking Market will be in High Demand
6.2 Effective Agents in Pre-Clinical Stage
      6.2.1 Benztropine analogues
6.3 Agents in Phase I
      6.3.1 EVT 302
      6.3.2 400 Patient European Study of TA-NIC Could Lead to Exciting New Drug
6.4 Agents in Phase II
      6.4.1 GSK’s 468816 May Still Have Hope
      6.4.2 ADX 10061 Initiates Proof-of-Concept Study in the U.S
      6.4.3 Surinabant (SR147778)
      6.4.4 The Move of Selegiline to Combat Smoking
      6.4.5 NicVax Meets Phase IIb Primary Endpoint Targets
      6.4.6 NicQb to Utilise Immunodrug Technology
      6.4.7 Somaxon’s Nalmefene Shows Successful Signs in Phase II
6.5 Sanofi’s Dianicline in Phase III
6.6 Acomplia (Rimonabant) has European Approval but still Waiting on FDA
6.7 Summary of Pipeline Products

7. Future Therapies
7.1 MAO-B Inhibitors – to Lessen the Shock of Withdrawal
7.2 Nicotine Metabolism Inhibitors
7.3 Vaccines to Stop Nicotine Reaching the Brain

8. The World Anti-Smoking Product Market, 2007-2012
8.1 The Worldwide Anti-Smoking Product Market, 2007-2012
8.2 NRTs Dominate the Anti-Smoking Products Market
8.3 Market Drivers
8.4 Market Restraints
8.5 Market Opportunities – Is there enough Potential for New Products

9. Key National Markets
9.1 North American Market
     9.1.1 US
              9.1.1.1 Smoking Prevalence in the U.S
              9.1.1.2 Smoking Ban in 52 U.S States
              9.1.1.3 Top Selling Products in the U.S Market
              9.1.1.4 Future of the Market
              9.1.1.5 Market Analysis
     9.1.2 Canada
              9.1.2.1 Smoking Prevalence in Canada
              9.1.2.2 The Government’s Sweeping Anti-Tobacco Legislation
              9.1.2.3 Top Selling Products in the Canadian Market
              9.1.2.4 Future of the Market
              9.1.2.5 Market Analysis
9.2 European Market
      9.2.1 UK 
              9.2.1.1 Smoking Prevalence in the UK
              9.2.1.2 New Smoking Ban Legislation to hit the UK in July
              9.2.1.3 Top Selling Products in the UK Market
              9.2.1.4 Future of the Market
              9.2.1.5 Market Analysis
      9.2.2 France
             9.2.2.1 Smoking Prevalence in France
             9.2.2.2 Tightening of Smoking Ban
             9.2.2.3 Top Selling Products in the French Market
             9.2.2.4 Future of the Market
             9.2.2.5 Market Analysis
     9.2.3 Sweden  
             9.2.3.1 Snus, a new Tobacco Perhaps?
             9.2.3.2 Governement Funding Money to Strengthen Anti-Smoking Measures
             9.2.3.3 Top Selling Products in the Swedish Market
             9.2.3.4 Future of the Market
             9.2.3.5 Market Analysis
    9.2.4 Germany
             9.2.4.1 Smoking Prevalence in Germany
             9.2.4.2 Still a Relative Haven for Smokers
             9.2.4.3 Top Selling Products in the German Market
             9.2.4.4 Future of the Market
             9.2.4.5 Market Analysis
   9.2.5 Spain
            9.2.5.1 Smoking Prevalence in Spain
            9.2.5.2 New Law Protects Children & Non-Smokers
            9.2.5.3 Top Selling Products in the Spanish Market
            9.2.5.4 Future of the Market
            9.2.5.5 Market Analysis
    9.2.6 Italy
            9.2.6.1 Smoking Prevalence in Italy
            9.2.6.2 Third EU Country to Introduce Ban
            9.2.6.3 Top Selling Products in the Italian Market
            9.2.6.4 Future of the Market
            9.2.6.5 Market Analysis
9.3 Asia/Australasia Market
     9.3.1 Australia
              9.3.1.1 Smoking Prevalence in Australia
              9.3.1.2 A New $1.2 Million Anti-Smoking Campaign to be Launched
              9.3.1.3 Top Selling Products in the Australian Market
              9.3.1.4 Future of the Market
              9.3.1.5 Market Analysis
     9.3.2 Japan
              9.3.2.1 Smoking Prevalence in Japan
              9.3.2.2 One of the Weakest Anti-Tobacco Laws
              9.3.2.3 Top Selling Products in the Japanese Market
              9.3.2.4 Future of the Market
              9.3.2.5 Market Analysis
9.4 Latin American Market
9.5 Summary of the National Markets

10. Company Profiles
10.1 Leading Companies
        10.1.1 GSK
        10.1.2 J&J
        10.1.3 Pfizer
        10.1.4 Novartis
        10.1.5 Watson
        10.1.6 Takeda

11. Conclusion

List of Tables
Table 5.1 Nicotine gum products available and 2006 sales ($m)
Table 5.2 World Revenue ($m) for Nicorette, 2007-2012
Table 5.3 Nicotine Inhaler product and 2006 sales ($m)
Table 5.4 Nicotine patch products available and 2006 sales ($m)
Table 5.5 Nicotine lozenge products available and 2006 sales ($m)
Table 5.6 Nicotine nasal spray product and 2006 sales ($m)
Table 5.7 Anti-smoking product summary and 2006 sales
Table 5.8 Zyban World Revenue Forecast ($m), 2007-2012
Table 5.9 Anti-smoking therapies comparison, 2007
Table 5.10 Chantix/Champix World Revenue Forecast ($m), 2007-2012

Table 6.1 Anti-smoking products in the pre-clinical stage, 2007
Table 6.2 Anti-smoking products in Phase I, 2007
Table 6.3 Anti-smoking products in Phase II, 2007
Table 6.4 Summary of anti-smoking products in the pipeline, 2007

Table 8.1 The Worldwide Anti-Smoking Products Market Forecast ($m), 2007-2012
Table 8.2 World Anti-Smoking Products Market Forecast by Therapy ($m), 2007-2012
Table 8.3 Anti-Smoking Therapy Market Share (%), 2006, 2009, 2012

Table 9.1 The North American Anti-Smoking Market Forecast ($m), 2007-2012
Table 9.2 The U.S Anti-Smoking Market Forecast ($m), 2007-2012
Table 9.3 The Canadian Anti-Smoking Market Forecast ($m), 2007-2012
Table 9.4 The European Anti-Smoking Market Forecast ($m), 2007-2012
Table 9.5 The U.K Anti-Smoking Market Forecast ($m), 2007-2012
Table 9.6 The French Anti-Smoking Market Forecast ($m), 2007-2012
Table 9.7 The Swedish Anti-Smoking Market Forecast ($m), 2007-2012
Table 9.8 The German Anti-Smoking Market Forecast ($m), 2007-2012
Table 9.9 The Spanish Anti-Smoking Market Forecast ($m), 2007-2012
Table 9.10 The Italian Anti-Smoking Market Forecast ($m), 2007-2012
Table 9.11 The Asia/Australasia Anti-Smoking Market Forecast ($m), 2007-2012
Table 9.12 The Australian Anti-Smoking Market Forecast ($m), 2007-2012
Table 9.13 The Japanese Anti-Smoking Market Forecast ($m), 2007-2012
Table 9.14 The Latin American Anti-Smoking Market Forecast ($ m), 2007-2012
Table 9.15 Summary of Regional and Country Breakdown of the World Anti-Smoking Market ($m), 2007-2012

Table 10.1 GSK’s anti-smoking product sales ($m), 2006
Table 10.2 J&J anti-smoking product sales ($m), 2006 
Table 10.3 Pfizer’s anti-smoking product sales ($m), 2006 
Table 10.4 Novartis anti-smoking product sales ($m), 2006 
Table 10.5 Watson anti-smoking product sales ($m), 2006 

List of Graphs
Graph 5.1 Nicotine gum products and 2006 global revenue ($m)
Graph 5.2 Nicorette Revenue Forecast ($m), 2007-2012
Graph 5.3 Nicorette Growth Forecast (%), 2007-2012
Graph 5.4 Nicotine patch products and 2006 global revenue ($m)
Graph 5.5 Nicotine lozenge products and 2006 global revenue ($m)
Graph 5.6: Zyban Revenue Forecast ($m), 2007-2012
Graph 5.7: Zyban Growth Forecast (%), 2007-2012
Graph 5.8:  Chantix/Champix Revenue Forecast ($m), 2007-2012
Graph 5.9:  Chantix/Champix Growth Forecast (%), 2007-2012

Graph 8.1 Total World Anti-Smoking Products Market Revenue ($m), 2007-2012
Graph 8.2 Total World Anti-Smoking Products Market Growth Rate (%), 2007-2012

Graph 9.1 The North American Anti-Smoking Market Revenue Forecast ($m), 2007-2012
Graph 9.2 The North American Anti-Smoking Market Growth Forecast (%), 2007-2012
Graph 9.3 Top anti-smoking product sales in the U.S market ($m), 2003-2006
Graph 9.4 The U.S Anti-Smoking Market Revenue Forecast ($m), 2007-2012
Graph 9.5 The U.S Anti-Smoking Market Growth Forecast (%), 2007-2012
Graph 9.6 Top anti-smoking product sales in the Canadian market ($m), 2003-2006
Graph 9.7 The Canadian Anti-Smoking Market Revenue Forecast ($m), 2007-2012
Graph 9.8 The Canadian Anti-Smoking Market Growth Forecast (%), 2007-2012
Graph 9.9 Top anti-smoking product sales in the UK market ($m), 2003-2006
Graph 9.10 The U.K Anti-Smoking Market Revenue Forecast ($m), 2007-2012
Graph 9.11 The U.K Anti-Smoking Market Growth Forecast (%), 2007-2012
Graph 9.12 Top anti-smoking product sales in the French market ($m), 2003-2006
Graph 9.13 The French Anti-Smoking Market Revenue Forecast ($m), 2007-2012
Graph 9.14 The French Anti-Smoking Market Growth Forecast (%), 2007-2012
Graph 9.15 Top anti-smoking product sales in the Swedish market ($m), 2003-2006
Graph 9.16 The Swedish Anti-Smoking Market Revenue Forecast ($m), 2007-2012
Graph 9.17 The Swedish Anti-Smoking Market Growth Forecast (%), 2007-2012
Graph 9.18 Top anti-smoking product sales in the German market ($m), 2003-2006
Graph 9.19 The German Anti-Smoking Market Revenue Forecast ($m), 2007-2012
Graph 9.20 The German Anti-Smoking Market Growth Forecast (%), 2007-2012
Graph 9.21 Top anti-smoking product sales in the Spanish market ($m), 2003-2006
Graph 9.22 The Spanish Anti-Smoking Market Revenue Forecast ($m), 2007-2012
Graph 9.23 The Spanish Anti-Smoking Market Growth Forecast (%), 2007-2012
Graph 9.24 Top anti-smoking product sales in the Italian market ($m), 2003-2006
Graph 9.25 The Italian Anti-Smoking Market Revenue Forecast ($m), 2007-2012
Graph 9. 26 The Italian Anti-Smoking Market Growth Forecast (%), 2007-2012
Graph 9.27 Top anti-smoking product sales in the Australian market ($m), 2003-2006
Graph 9.28 The Australian Anti-Smoking Market Revenue Forecast ($m), 2007-2012
Graph 9.29 The Australian Anti-Smoking Market Growth Forecast (%), 2007-2012
Graph 9.30 Top anti-smoking product sales in the Japanese market ($m), 2003-2006
Graph 9.31 The Japanese Anti-Smoking Market Revenue Forecast ($m), 2007-2012
Graph 9.32 The Japanese Anti-Smoking Market Growth Forecast (%), 2007-2012

Graph 10.1 GSK’s Company Results ($bn), 2006
Graph 10.2 J&J’s Company Results ($bn), 2006
Graph 10.3 Pfizer’s Company Results ($bn), 2005
Graph 10.4 Novartis’ Company Results ($bn), 2006
Graph 10.5 Watson’s Company Results ($bn), 2005
Graph 10.6 Takeda’s Company Results ($bn), 2006

List of Charts
Chart 7.1 Diagram showing the conversion of nicotine into cotinine

Chart 8.1 Anti-Smoking Therapy Market Share (%), 2006
Chart 8.2 Anti-Smoking Therapy Market Share (%), 2009
Chart 8.3 Anti-Smoking Therapy Market Share (%), 2012

Organisations mentioned in this report include:
Action on Smoking and Health (ASH)
Addex
American Heart Association
Azevan
BNL
British American Tobacco
British Heart Foundation (BHF)
Cancer Research UK
Celtic Pharma
Centers for Disease Control and Prevention (CDC)
Chinoin
Choong Wae
Cytos
Dae Woong Pharm
Elder Pharma
European Agency for the Evaluation of Medicinal Products (EMEA)
Emra-Med
Esteve
Evotec
Food and Drug Administration (FDA)
Georgetown University
GSK
Guardian
Haymann
Health Products
HM Revenue & Customs (HMRC)
Imperial Tobacco
Johnson & Johnson (J&J)
Korea Green Cross
Lab unknown
Lehman Brothers
Major Pharm Corp
McNeil Consumer products
Merck KGAA
Nabi Pharmaceuticals
National Health Service (NHS)
National Institute for Clinical Excellence (NICE)
National Institutes of Health (NIH)
Novartis

Perrigo
Pfizer
Pharmacia & Upjohn Consumer Healthcare
Philip Morris
Pierre Fabre
Reynolds American
Riemser
Rockefeller University
Sanofi Aventis
Schering Plough
Sidus
Sigma Pharmaceutic
Sintong
Somaxon
Takeda
ThaiHealth
Tobacco Manufacturers' Association (TMA)
University of California
University of Kentucky
Watson
World Health Organization (WHO)
Yaupon